SCHEMBL23675397

SCHEMBL23675397

O=C(Nc1ccc(NCc2ccc(C(F)(F)F)cc2)cc1Cl)c1cc(Cl)ccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS4 Q9NRS4 13/20 0.65
P2RX1 P51575 7/20 0.65
P2RX4 Q99571 4/20 0.65
P2RX7 Q99572 4/20 0.65
MEN1 O00255 2/20 0.56
KDR P35968 2/20 0.56
KMT2A Q03164 2/20 0.56
IKBKB O14920 1/20 0.56
CHUK O15111 1/20 0.56
FLT3 P36888 1/20 0.56
MYLK Q15746 1/20 0.56
MAP4K5 Q9Y4K4 1/20 0.56
SLC2A1 P11166 1/20 0.53
HDAC1 Q13547 1/20 0.51
AURKA O14965 1/20 0.49
NPC1 O15118 1/20 0.49
PDPK1 O15530 1/20 0.49
JAK2 O60674 1/20 0.49
GMNN O75496 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30100476 1.00 TMPRSS4 (0.65) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30100514 0.92 TMPRSS4 (0.64) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL23675454 0.92 TMPRSS4 (0.64) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL26096971 0.90 P2RX1 (0.59) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL23675416 0.90 TMPRSS4 (0.59) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL23675407 0.89 TMPRSS4 (0.61) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL30100480 0.89 TMPRSS4 (0.61) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL23675418 0.89 P2RX1 (0.62) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL26096505 0.88 TMPRSS4 (0.57) TMPRSS4P2RX1P2RX4P2RX7MEN1
SCHEMBL26099973 0.88 MEN1 (0.54) TMPRSS4P2RX1P2RX4P2RX7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE TMPRSS4 526/4885P2RX1 3088/4885P2RX4 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.